CIBC initiated coverage on shares of Personalis (NASDAQ:PSNL) in a research report report published on Monday, FirstToMarketsRatingsTable reports. The firm issued an outperform rating and a $29.00 price target on the stock.
A number of other brokerages have also weighed in on PSNL. Cowen reissued a buy rating on shares of Avrobio in a report on Monday. Oppenheimer set a $110.00 price target on shares of Medtronic and gave the company a buy rating in a report on Monday. Morgan Stanley set a $70.00 price target on shares of Edison International and gave the company a hold rating in a report on Monday. Finally, Bank of America set a $68.00 price target on shares of Inphi and gave the company a buy rating in a report on Monday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $28.25.
NASDAQ:PSNL opened at $21.40 on Monday. Personalis has a 1 year low of $20.21 and a 1 year high of $31.88.
In related news, Director Ken Ludlum purchased 70,000 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average price of $17.00 per share, with a total value of $1,190,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Featured Story: Do Tariffs Work?
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.